Navigation Links
ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
Date:3/28/2008

ADDISON, Texas, March 28 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today announced that it has scheduled a conference call to discuss the fourth quarter 2007 financial results and provide a general business update on Tuesday, April 1, 2008 at 10:00 a.m. Eastern time.

To participate in the conference call, please dial (800) 357-0498 for international callers dial (850) 429-1388 (access code 9285#) five to ten minutes prior to the initiation of the teleconference. If you are unable to listen to the live broadcast a replay of the call will be available starting on April 1, 2008 two hours following the end of the call until April 8, 2008 at 11:59 p.m. Eastern Time. For the U.S. replay, please dial (800) 695-0697 for international callers dial (402) 220-1472 (access code 9285#).

Interested investors and others may also listen to the conference call replay through our Internet webcast, which may be accessed by visiting our website at http://www.uluruinc.com and clicking on the "Investor Relations" icon.

About ULURU Inc.:

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 and other report
'/>"/>

SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Reports Third Quarter 2007 Results
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
8. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
9. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
10. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
11. HEI, Inc. Announces Sale of RFID Division Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2008)...RNewswire-FirstCall/ -- Alseres,Pharmaceuticals, I...ll host a,conference call on Thursday, May 15th, 2...ng March 31, 2008 and discuss other matters relate.../cgi-bin/prnh/20070608/NEF043LOGO ), To access t...omestic,and 719-325-4817 international. The code f...
(Date:5/9/2008)...wire-USNewswire/ -- The following is a,statement o...r Tobacco-Free,Kids:, As a conference committee...egislation in Pennsylvania, we urge the committee ...o enact a strong smoke-free law that,covers all wo...lvanians,from the deadly dangers of secondhand smo...
(Date:5/9/2008)... for mothers, new treatments for elderly a priorit...Instances of Group B streptococcus, a major cause ...rcent among week-old infants, but rose by almost 5...ar period, according to a new study. , Group B...is in the first week of life. Prevention strategie...
(Date:5/9/2008)...nced to Recognize Outstanding Journalism in, Supp...ers Awareness and Unde...gh the weatherman predicted rain,that did not imp...in New,York,s Central Park on Saturday, April 26th...to raise money and spirits for Parkinson,s disease...
Breaking Medicine News(10 mins):Health News:Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call 2Health News:Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call 3Health News:Pennsylvania Conference Committee Should Approve Smoke-Free Bill That Covers All Workplaces and Protects All Workers 2Health News:Group B Strep Down Among Newborns, Up Among Adults 2Health News:14th Annual Parkinson's Unity Walk Most Successful Event to Date 2Health News:14th Annual Parkinson's Unity Walk Most Successful Event to Date 3
...t AIDS vaccine candidate designed specifically for...International AIDS Vaccine Initiative (IAVI) annou...ference in Durban, South Africa, that the Medicine...Kingdom has approved Phase I testing of a DNA vacc...
...y cleared for marketing a robotic device that enab... and reflux disease surgery while seated at a cons... can use hand grips and foot pedals on the console...he surgery using a variety of surgical tools. The ...
...lly invasive direct coronary artery bypass (MIDCAB...patient was awake. The operation was done under th... in discharging the patient early from the hospita...med the surgery said that patients who are operate...
...t high levels of cholesterol but low levels that a...t Low levels of Cholesterol maybe linked to depres...men with relatively low cholesterol levels were up...f severe depression. Edward Suarez, PhD from Duke...
Other Medicine News:
(Date:5/8/2008)...RNewswire-FirstCall/ -- VION PHARMACEUTICALS,INC....investigator-sponsored,Phase I/II clinical trial o...01M) in combination with cytarabine in elderly pat...leukemia (AML) and high-risk,myelodysplastic syndr...,direction of Ellen K. Ritchie, M.D. at The Weill-...
(Date:5/8/2008)...ancer Center Investigators to Assess BSI-201 ...nts -, BRISBANE, Calif., May 8 /- Bi...f Phase 2 clinical trial programs for its lead,pro...d major clinical trial,of BSI-201 that BiPar has l...g trials in breast and brain cancer., The company...
(Date:5/8/2008)...-FirstCall/ -- Go Healthy (Pink Sheets: GOHE),anno...th Cholesterade (R),in three medical settings with...s in 6 centers around the country. Dr. William Bry...st Hospital in the Texas Medical Center,will coord...he Team,Physician for the Houston Astros and the f...
(Date:5/7/2008)...re-FirstCall/ -- Arena Pharmaceuticals, Inc.,(Nasd...ical Co., Ltd.,initiated a Phase 1 clinical trial ...ip with Arena to develop compounds to treat psychi...l compound intended for the treatment of a,common ...our long-standing partner, Taisho,effectively con...
Breaking Medicine Technology:Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer 2Go Healthy Initiates Additional Clinical Tests on Cholesterade 2Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 2Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 3Diabetes in the Bedroom 3A Scarier than Halloween 3F 2844 1Diabetes in the Bedroom 3A Scarier than Halloween 3F 2844 2Parents can Help Young Superheroes Battle Cavities on Halloween Night 2842 1Parents can Help Young Superheroes Battle Cavities on Halloween Night 2842 2Nitec Pharma Expands Senior Management Team 1039 1Nitec Pharma Expands Senior Management Team 1039 2Nitec Pharma Expands Senior Management Team 1039 3Nitec Pharma Expands Senior Management Team 1039 4Prime Therapeutics Announces URAC Accreditation 2840 1Prime Therapeutics Announces URAC Accreditation 2840 2
...Data Presented at the Society for Investigative,De...e-FirstCall/ -- AGI,Dermatics today announced new ...sylase (OGG1) encapsulated in liposomes,enhances D...radiated skin cells. The data was presented at the...ive Dermatology, May 9 - 12,in Los Angeles, CA. ,...
...Poster Presented at Society for Investigative Derm... -- AGI Dermatics,recently announced new comparati...ells have the ability to recognize, transport and,...st oxidative,damage, and importantly, that (EGT) a...han idebenone, scavenging reactive oxygen,species ...
Other Medicine Technology:AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1,Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV,Irradiated Skin Cells 2AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin,Cells Have the Ability to Recognize, Transport and Utilize,L-ergothioneine (EGT) As A Protector Against Oxidative Damage 2
ELISA kit for Varicella-zoster IgG.
Inquire
The CALBIOTECH, INC. (CBI), Mumps IgM ELISA tests system is an enzyme linked immunosorbent assay (ELISA) for the detection of IgM class antibodies to Mumps in human serum or plasma.
...ntific Corporation announced the launch of the Ch...bi-directional cooled-tip catheter available in th...ysicians the benefits of cooled ablation technolog...n Scientific Blazer(R) catheter platform. ,Coole...
Medicine Products: